Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 5
2022 4
2023 6
2024 11
2025 12
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean f shaker (124 results)?
Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.
Pelkmans W, Shekari M, Brugulat-Serrat A, Sánchez-Benavides G, Minguillón C, Fauria K, Molinuevo JL, Grau-Rivera O, González Escalante A, Kollmorgen G, Carboni M, Ashton NJ, Zetterberg H, Blennow K, Suarez-Calvet M, Gispert JD; ALFA study. Pelkmans W, et al. Alzheimers Dement. 2024 Jan;20(1):483-493. doi: 10.1002/alz.13450. Epub 2023 Sep 10. Alzheimers Dement. 2024. PMID: 37690071 Free PMC article.
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, Stevenson J, Rahmouni N, Pallen V, Poltronetti NM, Salvadó G, Shekari M, Operto G, Gispert JD, Minguillon C, Fauria K, Kollmorgen G, Suridjan I, Zimmer ER, Zetterberg H, Molinuevo JL, Paquet C, Rosa-Neto P, Blennow K, Suárez-Calvet M; Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort. Benedet AL, et al. JAMA Neurol. 2021 Dec 1;78(12):1471-1483. doi: 10.1001/jamaneurol.2021.3671. JAMA Neurol. 2021. PMID: 34661615 Free PMC article.
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.
Ossenkoppele R, Coomans EM, Apostolova LG, Baker SL, Barthel H, Beach TG, Benzinger TLS, Betthauser T, Bischof GN, Bottlaender M, Bourgeat P, den Braber A, Brendel M, Brickman AM, Cash DM, Carrillo MC, Coath W, Christian BT, Dickerson BC, Dore V, Drzezga A, Feizpour A, van der Flier WM, Franzmeier N, Frisoni GB, Garibotto V, van de Giessen E, Domingo-Gispert J, Gnoerich J, Gu Y, Guan Y, Hanseeuw BJ, Harrison TM, Jack CR, Jaeger E, Jagust WJ, Jansen WJ, La Joie R, Johnson KA, Johnson SC, Kennedy IA, Kim JP, van Laere K, Lagarde J, Lao P, Luchsinger JA, Kern S, Kreisl WC, Malotaux V, Malpetti M, Manly JJ, Mao X, Mattsson-Carlgren N; Mayo Clinic Study on Aging; Messerschmidt K, Minguillon C, Mormino EM, O'Brien JT, Palmqvist S, Peretti DE, Petersen RC, Pijnenburg YAL, Pontecorvo MJ, Poirier J; PREVENT-AD Research Group; Rabinovici GD, Rahmouni N, Risacher SL, Rosa-Neto P, Rosen H, Rowe CC, Rowe JB, Rullmann M, Salman Y, Sarazin M, Saykin AJ, Schneider JA, Schöll M, Schott JM, Seo SW, Serrano GE, Shcherbinin S, Shekari M, Skoog I, Smith R, Sperling RA, Spruyt L, Stomrud E, Strandberg O, Therriault J, Xie F, Vandenberghe R, Villemagne VL, Villeneuve S, Visser PJ, Vossler H, Young CB, G… See abstract for full author list ➔ Ossenkoppele R, et al. Nat Neurosci. 2025 Aug;28(8):1610-1621. doi: 10.1038/s41593-025-02000-6. Epub 2025 Jul 16. Nat Neurosci. 2025. PMID: 40670684 Free PMC article.
Associations of (18) F-RO-948 Tau PET with Fluid AD Biomarkers, Centiloid, and Cognition in the Early AD Continuum.
Shekari M, González Escalante A, Milà-Alomà M, Falcon C, López-Martos D, Sánchez-Benavides G, Brugulat-Serrat A, Niñerola-Baizán A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Montoliu-Gaya L, Snellman A, Day TA, Dage JL, Ortiz-Romero P, Tonietto M, Borroni E, Klein G, Kollmorgen G, Carboni M, Quijano-Rubio C, Vanmechelen E, Minguillón C, Fauria K, Perissinotti A, Molinuevo JL, Zetterberg H, Blennow K, Grau-Rivera O, Suárez-Calvet M, Domingo Gispert J; ALFA Study. Shekari M, et al. medRxiv [Preprint]. 2025 Jul 11:2025.07.09.25331011. doi: 10.1101/2025.07.09.25331011. medRxiv. 2025. PMID: 40672479 Free PMC article. Preprint.
METHODS: Ninety-nine CU individuals from the ALFA+ cohort underwent tau PET using (18) F-RO-948, amyloid PET, MRI, cognitive assessments, and (CSF)/plasma biomarkers. Tau PET SUVRs calculated in Braak regions, and associations with AD biomarkers were assessed. ...For CSF b …
METHODS: Ninety-nine CU individuals from the ALFA+ cohort underwent tau PET using (18) F-RO-948, amyloid PET, MRI, cognitive assessme …
Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning.
Lorenzini L, Tranfa M, Pieperhoff L, Masserini F, Ten Kate M, Collij LE, Pontillo G, Luckett ES, Wink AM, Mutsaerts HJ, Oliveira TG, Altomare D, Boada M, den Braber A, Birck C, Buckley C, Farrar G, van der Flier W, Frisoni GB, Gismondi R, Gispert JD, Hanseeuw BJ, Jessen F, Marquié M, Mett A, Ritchie C, Salvadó G, Schöll M, Shekari M, Stephens AW, Tijms BM, Vállez García D, Vandenberghe R, Visser PJ, Roccatagliata L, Oxtoby NP, Pardini M, Barkhof F. Lorenzini L, et al. Alzheimers Dement. 2025 Oct;21(10):e70762. doi: 10.1002/alz.70762. Alzheimers Dement. 2025. PMID: 41085135 Free PMC article.
Quantification of [(18) F]florbetaben amyloid-PET imaging in a mixed memory clinic population: The ABIDE project.
Collij LE, Salvadó G, de Wilde A, Altomare D, Shekari M, Gispert JD, Bullich S, Stephens A, Barkhof F, Scheltens P, Bouwman F, van der Flier WM. Collij LE, et al. Alzheimers Dement. 2023 Jun;19(6):2397-2407. doi: 10.1002/alz.12886. Epub 2022 Dec 7. Alzheimers Dement. 2023. PMID: 36478646
INTRODUCTION: We investigated amyloid-burden quantification in a mixed memory clinic population. METHODS: [(18) F]Florbetaben amyloid-PET (positron emission tomography) scans of 348 patients were visually read and quantified using the Centiloid (CL) method. ...RESULTS: CL …
INTRODUCTION: We investigated amyloid-burden quantification in a mixed memory clinic population. METHODS: [(18) F]Florbetaben amyloid …
Grief and Economic Stressors by Sex, Gender, and Education: Associations With Alzheimer Disease-Related Outcomes.
Palpatzis E, Akinci M, Garcia-Prat M, Blennow K, Zetterberg H, Quijano-Rubio C, Kollmorgen G, Wild N, Gispert JD, Suárez-Calvet M, Grau-Rivera O, Fauria K, Brugulat-Serrat A, Sanchez-Benavides G, Arenaza-Urquijo EM; ALFA study. Palpatzis E, et al. Neurology. 2025 Apr 22;104(8):e213377. doi: 10.1212/WNL.0000000000213377. Epub 2025 Mar 31. Neurology. 2025. PMID: 40163795 Free PMC article.
Physical activity changes during midlife link to brain integrity and amyloid burden.
Akinci M, Aguilar-Domínguez P, Palpatzis E, Shekari M, García-Prat M, Deulofeu C, Fauria K, García-Aymerich J, Gispert JD, Suárez-Calvet M, Grau-Rivera O, Sánchez-Benavides G, Arenaza-Urquijo EM; ALFA study. Akinci M, et al. Alzheimers Dement. 2025 May;21(5):e70007. doi: 10.1002/alz.70007. Alzheimers Dement. 2025. PMID: 40304268 Free PMC article.
Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease.
Argiris G, Akinci M, Peña-Gómez C, Palpatzis E, Garcia-Prat M, Shekari M, Blennow K, Zetterberg H, Kollmorgen G, Quijano-Rubio C, Ashton NJ, Karikari TK, Brinkmalm-Westman A, Lantero-Rodriguez J, Fauria K, Sánchez-Benavides G, Grau-Rivera O, Suárez-Calvet M, Arenaza-Urquijo EM, Study FTA. Argiris G, et al. Alzheimers Res Ther. 2024 Dec 23;16(1):274. doi: 10.1186/s13195-024-01629-y. Alzheimers Res Ther. 2024. PMID: 39716329 Free PMC article.
Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease.
Hönig M, Altomare D, Caprioglio C, Collij L, Barkhof F, Van Berckel B, Scheltens P, Farrar G, Battle MR, Theis H, Giehl K, Bischof GN, Garibotto V, Molinuevo JLL, Grau-Rivera O, Delrieu J, Payoux P, Demonet JF, Nordberg AK, Savitcheva I, Walker Z, Edison P, Stephens AW, Gismondi R, Jessen F, Buckley CJ, Gispert JD, Frisoni GB, Drzezga A; AMYPAD Consortium. Hönig M, et al. Neurology. 2024 Mar 26;102(6):e208053. doi: 10.1212/WNL.0000000000208053. Epub 2024 Feb 20. Neurology. 2024. PMID: 38377442 Free PMC article.
In this study, we assessed whether this observation is also present in potential preclinical AD stages, namely in individuals with subjective cognitive decline and clinical features increasing AD likelihood (SCD+). METHODS: Amyloid-PET information ([(18)F]Flutemetamol or [ …
In this study, we assessed whether this observation is also present in potential preclinical AD stages, namely in individuals with subjectiv …
35 results